Robert L. Coleman, M.D., FACOG, FACS
Dr. Coleman is professor of gynecologic oncology and vice-chair of clinical research at The University of Texas MD Anderson Cancer Center in Houston, Texas. He is a world-renown expert who has distinguished himself as a key opinion leader in cancers of the female genital tract. As a key opinion leader, he is a frequently invited lecturer for national and international conferences and meetings where he continues to foster global scientific collaboration. He is the MD Anderson’s Gynecologic Oncology Group (GOG) Principal Investigator (PI) and is PI or Co-PI for several GOG prospective clinical trials including a national, multicenter, randomized trial evaluating chemotherapy and surgery for recurrent ovarian cancer, as well as, numerous investigator-initiated clinical studies of novel chemotherapeutic and biological compounds in cancers of the ovary, cervix and uterus. Dr. Coleman was the Principal Investigator for the just completed Phase 2A clinical trial for EP-100 in patients with advanced ovarian cancer. He will continue to be the Principal Investigator for the proposed Phase 2B trial for EP-100.
Dr. Coleman has authored and co-authored over 400 scientific publications, including over 130 peer-reviewed articles, numerous book chapters, monographs, invited articles and textbooks. He is a past President of the Society of Gynecologic Oncology. He currently serves on the Editorial Board of several peer-reviewed scientific publications. He is an active member of many national organizations including the Society of Gynecologic Oncology, the American College of Surgeons, American Association for Cancer Research and the American Society of Clinical Oncology. He also serves several International Organizations, such as the International Gynecologic Cancer Society, European Society of Gynecologic Oncology and the European Society of Medical Oncology. Dr. Coleman serves as the vice-chairman of the Department of Gynecologic Oncology Clinical Research, Director of Developmental Therapeutics and Research Administration Committees, is a member of the Blanton-Davis Ovarian Cancer Research Program Executive Committee and is a Member of the Board for the Foundation for Women’s Cancer. In June 2010, he was appointed to the Ann Rife Cox Chair in Gynecology and is a member of the M.D. Anderson Cancer Center’s Center for RNA Interference and Non-Coding RNA.
Mark Pegram, M.D.
Dr. Pegram is currently the first Director of the Breast Cancer Oncology Program at Stanford Women’s Cancer Center in Stanford, California and the Susy Yuan-Huey Professor of Oncology. He is also the co-Director of Stanford’s Molecular Therapeutics Program.
Dr. Pegram is world-renown and recognized clinician and scholar in translational breast cancer research and a leader in translational medicine. He and his colleagues were instrumental in developing Herceptin as a treatment for Her2+ breast cancer and demonstrated efficacies by combining Herceptin with chemotherapies in pre-clinical experiments. Clinical trials conducted by Dr. Pegram and his colleagues demonstrated that Herceptin improved survival rates and even cured some breast cancer patients, representing a premier example of bench-to-bedside translational research. Dr. Pegram’s current research efforts continue to focus on the cancer associated gene that encodes Her2 to develop new treatments to target these cancer cells as well as evaluating strategies to target estrogen receptors on breast cancers. Dr. Pegram has published more than 80 papers and conducted more than 20 clinical trials.
Dr. Pegram is the recipient of the Sylvester Outstanding Cancer Research Award in 2011 and The Celebrity Cruises Award of the Breast Cancer Research Foundation (2013-2014). Additional prestigious awards include the 6th Annual Connie Moskow Memorial Lectureship (2012), the John G Kuhn Lecture on the Hematology/Oncology Pharmacy Association (2013) and the Keynote Lecture of the American Radium Society 94th Annual Meeting in 2012.
Dr. Pegram served as Chair in the Department of Defense Breast Cancer Research Program Integration Panel, Congressionally Directed Medical Research Programs, US Army Research and Materiel Command in 2012.
Daniel Von Hoff, M.D., FACP
Dr. Von Hoff is currently Physician in Chief and Director of Translational Research at TGen (Translational Genomics Research Institute) in Phoenix, Arizona. He is also Chief Scientific Officer for US Oncology and for HonorHealth’s Clinical Research Institute. He is also a Clinical Professor of Medicine, University of Arizona. He also holds an appointment as a Professor of Medicine at Mayo Clinic in Scottsdale, Arizona.
Dr. Von Hoff is world-renown and recognized expert in development of new anticancer agents, both in the clinic and in the laboratory. He and his colleagues were involved in the beginning of the development of many of the agents we now use routinely, including: mitoxantrone, fludarabine, paclitaxel, docetaxel, gemcitabine, irinotecan, nelarabine, capecitabine, lapatinib and others. He was a founder of ILEXTM Oncology, Inc., that was acquired by Genzyme after their products, alemtuzumab (CampathTM) and clofarabine were approved by the FDA for patients with leukemia. At present, he and his colleagues are concentrating on the development of molecularly targeted therapies for patients with pancreatic and other advanced cancers.
Dr. Von Hoff has published more than 648 papers, 138 book chapters and over 1085 abstracts. Dr. Von Hoff received the 2010 David A. Karnofsky Memorial Award from the American Society of Clinical Oncology for his outstanding contributions to cancer research leading to significant improvement in patient care.
Dr. Von Hoff was appointed to President Bush’s National Cancer Advisory Board in 2004-2010. He is the past President of the American Association for Cancer Research (AACR, the world’s largest cancer research organization), a Fellow of the American College of Physicians, and a member and past board member of the American Society of Clinical Oncology. Dr. Von Hoff is founder and the Editor Emeritus of Investigational New Drugs – The Journal of New Anticancer Agents; and, past Editor-in-Chief of Molecular Cancer Therapeutics. He is a co-founder of the AACR/ASCO Methods in Clinical Cancer Research Workshop. He is also proud to have been a mentor and teacher for multiple medical students, medical oncology fellows, graduate students, and post-doctoral fellows